27876598|t|Antithrombotic activity of Batroxase, a metalloprotease from Bothrops atrox venom, in a model of venous thrombosis
27876598|a|Snake venoms are great sources of bioactive molecules, which may be used as models for new drugs. Toxins that interfere in hemostasis have received considerable attention over the years. This study aimed at the evaluation of the antithrombotic activity of Batroxase, a P-I metalloprotease from Bothrops atrox venom, in an animal model of venous thrombosis. The antithrombotic activity of Batroxase was tested in vivo in a model based on two factors of the Virchow's Triad: blood flow alterations (partial stenosis of the inferior vena cava), and vessel wall injury (10% ferric chloride for 5min), in comparison with sodium heparin (positive control) and saline (negative control). Bleeding / clotting time was assessed by a tail bleeding assay. The immunogenicity of Batroxase was also analyzed. Batroxase (12mg/kg) reduced thrombus formation in 81%, similarly to heparin (100U/kg), which reduced it in 85% in comparison with the saline group. Both Batroxase and heparin increased bleeding / clotting time in approximately 3 fold. Immunizations of rabbits with Batroxase do not result in detectable levels of antibodies against this metalloprotease. Batroxase presents antithrombotic activity in vivo. Moreover, its lack of immunogenicity increases the interest on its possible therapeutic potential over thrombogenic disorders.
27876598	0	23	Antithrombotic activity	T033	C0243095
27876598	27	36	Batroxase	T116,T126,T131	C4278231
27876598	40	55	metalloprotease	T116,T126	C0025543
27876598	61	81	Bothrops atrox venom	T109,T121	C4033446
27876598	88	93	model	T008	C0599779
27876598	97	114	venous thrombosis	T046	C0042487
27876598	115	127	Snake venoms	T123,T131	C0037380
27876598	149	168	bioactive molecules	T167	C3714412
27876598	191	197	models	T170	C3161035
27876598	206	211	drugs	T121	C0013227
27876598	213	219	Toxins	T123,T131	C0040549
27876598	238	248	hemostasis	T047	C0005779
27876598	295	300	years	T079	C0439234
27876598	307	312	study	T062	C2603343
27876598	326	336	evaluation	T078	C1550157
27876598	344	367	antithrombotic activity	T033	C0243095
27876598	371	380	Batroxase	T116,T126,T131	C4278231
27876598	384	403	P-I metalloprotease	T116,T126	C0025543
27876598	409	429	Bothrops atrox venom	T109,T121	C4033446
27876598	437	449	animal model	T008	C0599779
27876598	453	470	venous thrombosis	T046	C0042487
27876598	476	499	antithrombotic activity	T033	C0243095
27876598	503	512	Batroxase	T116,T126,T131	C4278231
27876598	524	531	in vivo	T082	C1515655
27876598	537	542	model	T008	C0599779
27876598	556	563	factors	T169	C1521761
27876598	571	586	Virchow's Triad	T170	C0282574
27876598	588	598	blood flow	T039	C0232338
27876598	612	628	partial stenosis	T020	C0333183
27876598	636	654	inferior vena cava	T023	C0042458
27876598	661	672	vessel wall	T023	C0229962
27876598	673	679	injury	T037	C0178314
27876598	685	700	ferric chloride	T121,T197	C0060229
27876598	731	745	sodium heparin	T109,T121	C0037513
27876598	747	763	positive control	T077	C1883676
27876598	769	775	saline	T167	C0036082
27876598	777	793	negative control	T077	C1947986
27876598	796	804	Bleeding	T201	C0550585
27876598	807	820	clotting time	T034	C2266672
27876598	844	858	bleeding assay	T046	C0019080
27876598	864	878	immunogenicity	T044	C1148560
27876598	882	891	Batroxase	T116,T126,T131	C4278231
27876598	911	920	Batroxase	T116,T126,T131	C4278231
27876598	939	957	thrombus formation	T033	C0243095
27876598	979	986	heparin	T109,T121,T123	C0019134
27876598	1045	1051	saline	T167	C0036082
27876598	1052	1057	group	T078	C0441833
27876598	1064	1073	Batroxase	T116,T126,T131	C4278231
27876598	1078	1085	heparin	T109,T121,T123	C0019134
27876598	1096	1104	bleeding	T201	C0550585
27876598	1107	1120	clotting time	T034	C2266672
27876598	1146	1159	Immunizations	T061	C0020971
27876598	1163	1170	rabbits	T015	C3887509
27876598	1176	1185	Batroxase	T116,T126,T131	C4278231
27876598	1214	1220	levels	T080	C0441889
27876598	1224	1234	antibodies	T116,T129	C0003241
27876598	1248	1263	metalloprotease	T116,T126	C0025543
27876598	1265	1274	Batroxase	T116,T126,T131	C4278231
27876598	1284	1307	antithrombotic activity	T033	C0243095
27876598	1308	1315	in vivo	T082	C1515655
27876598	1339	1353	immunogenicity	T044	C1148560
27876598	1393	1414	therapeutic potential	T080	C0205556
27876598	1420	1442	thrombogenic disorders	T047	C0012634